ImmunoVision Technologies

ImmunoVision Technologies (IVT) is a spatial biology company that developed the Multiplexed Ion Beam Imaging (MIBI) platform. Founded by researchers from Stanford University, the company's technology enables high-plex protein detection in tissue samples using secondary ion mass spectrometry (SIMS). This allows for the simultaneous analysis of dozens of biomarkers within the tumor microenvironment at subcellular resolution, providing deep insights into cellular interactions and spatial organization. IVT was acquired by Indivumed in 2018 to integrate its high-content imaging capabilities into Indivumed's precision oncology and drug discovery service offerings.